PF 4605412

Drug Profile

PF 4605412

Alternative Names: PF-04605412; PF-4605412

Latest Information Update: 03 May 2013

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Pfizer
  • Class Antibodies; Antineoplastics; Monoclonal antibodies
  • Mechanism of Action Immunostimulants; Integrin alpha 5 beta 1 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Solid tumours

Most Recent Events

  • 26 Feb 2013 Discontinued - Phase-I for Solid tumours in United Kingdom (IV)
  • 26 Feb 2013 Discontinued - Phase-I for Solid tumours in USA (IV)
  • 26 Feb 2013 Pfizer terminates phase I trial in Solid tumours in the USA and the UK (NCT00915278)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top